Agios Pharmaceuticals has filed a patent for a method of treating lymphomas using an anti-cancer agent and therapy. The patent claims that administering the anti-cancer agent, represented by Formula (I), along with the therapy is effective in treating lymphoma in subjects. GlobalData’s report on Agios Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agios Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Agios Pharmaceuticals's grant share as of September 2023 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating lymphoma using anti-cancer agent and therapy
A recently filed patent (Publication Number: US20230285365A1) describes a method for treating lymphoma in a subject by administering an effective amount of an anti-cancer agent and an effective amount of an anti-cancer therapy. The anti-cancer agent is represented by Formula (I). The method can be used for various types of lymphoma, including Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell lymphoma, T-cell lymphoma, and cutaneous T-cell lymphoma. Specific subtypes of lymphoma that can be treated using this method include follicular lymphoma, DLBCL, MCL, Burkitt, mycosis fungoide, PTCL, AITL, ALCL, EATL, and hepatosplenic gamma/delta T-cell lymphoma.
The patent claims also mention that the anti-cancer agent and the anti-cancer therapy can be administered simultaneously or sequentially, using the same or different formulations. Additionally, the patent specifies that the anti-cancer agent can be the tris(hydroxymethyl)aminomethane salt or the sodium salt of the compound represented by Formula (I). The anti-cancer therapy includes doxorubicin hydrochloride and vincristine sulfate.
This patent presents a method for treating lymphoma by combining an anti-cancer agent and an anti-cancer therapy. The method is applicable to various types of lymphoma, including both Hodgkin and non-Hodgkin lymphomas, as well as specific subtypes such as DLBCL, MCL, and Burkitt lymphoma. The patent also provides flexibility in the administration of the treatment, allowing for simultaneous or sequential administration using different formulations. The anti-cancer agent can be either the tris(hydroxymethyl)aminomethane salt or the sodium salt of the compound represented by Formula (I). The anti-cancer therapy includes doxorubicin hydrochloride and vincristine sulfate. This patent may have significant implications for the development of new treatment options for lymphoma patients, potentially improving outcomes and quality of life.
To know more about GlobalData’s detailed insights on Agios Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
